What does Baxter International do and what are its main business segments?

What is Baxter International's gross profit margin?

What is Baxter International's latest dividend and current dividend yield?

What factors drove the changes in Baxter International's revenue and profit?

What guidance did Baxter International's management provide for the next earnings period?

What were the key takeaways from Baxter International's earnings call?

Did Baxter International beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Baxter International next quarter?

- **Revenue Growth Mixed**: Q4 2025 sales up 8% reported/3% operational, but EPS missed due to margin pressure and tax rate hike.
- **Key Risks**: Novum LVP shipment hold ($40M+ annual risk), IV Solutions demand baseline decline, and pharma supply chain challenges.
- **Strategic Actions**: Simplified operating model, $80M tariff mitigation, and $130-140M TSA income in 2026.
- **2026 Outlook**: Flat to +1% sales, 13-14% operating margin, and back-half weighted recovery with Q1 as most challenging quarter.
- **Cash Flow Focus**: Free cash flow improvement in 2026, with $438M in 2025 and $456M in Q4.


**【CEO Summary Section】**
- **Revenue Performance**: Q4 2025 global sales from continuing operations totaled $3 billion, up 8% on a reported basis and 3% on an operational basis. Adjusted EPS was $0.44, missing expectations due to margin pressure and a higher tax rate.
- **Challenges**: Margins were impacted by unfavorable product mix, nonrecurring inventory adjustments, and the ongoing Novum LVP shipment hold. The IV Solutions business faced a new demand baseline due to fluid conservation practices post-Hurricane Helene.
- **Strategic Initiatives**: 
  - **Operating Model Simplification**: Removed segment management layer, embedding functional roles directly into businesses for P&L accountability.
  - **Innovation Focus**: Heightened R&D investment (≥ historical levels) and launches like the Dynamo Series stretcher.
  - **Continuous Improvement**: Launched Baxter GPS (Growth & Performance System) to drive efficiency and customer value.

**【CFO Financial Commentary】**
- **Top Line**: Full-year 2026 sales expected to be flat to +1% on a reported basis, with organic growth flat due to headwinds from Novum and pharma softness.
- **Segment Outlook**: 
  - **Medical Products & Therapies (MPT)**: Flat to slightly up, constrained by Novum uncertainty.
  - **Healthcare Systems & Technologies (HST)**: Low single-digit growth driven by new product launches (e.g., Connex 360).
  - **Pharmaceuticals**: Flat, with pressure in injectables and anesthesia.
- **Margin Guidance**: Adjusted operating margin 13-14%, down 340bps YoY due to gross margin compression and tariffs ($80M headwind).
- **Cash Flow**: Free cash flow expected to improve in 2026, back-half weighted, with Q1 facing absorption headwinds from high-cost inventory.
- **TSA Runoff**: Stranded costs to be eliminated by end-2027, with TSA income declining from $50M in Q4 to $130-140M annually.

**【Q&A Key Highlights】**
- **Novum LVP Uncertainty**: Customers awaiting corrections; ship/install hold expected to remain in 2026, creating $40M+ annual revenue risk.
- **Gross Margin Challenges**: Q1 2026 will see 900bps YoY decline due to unfavorable mix, tariffs, and absorption of high-cost inventory.
- **Pharma Margin Pressures**: Injectables & Anesthesia softness and supply chain issues to persist, offset by Drug Compounding growth (18% Q4).
- **Balance Sheet Focus**: Free cash flow prioritized for deleveraging; 2026 interest expense up $32M YoY due to debt-neutral transactions.
- **Innovation Pipeline**: Upcoming launches (Dynamo stretcher, Pure-Vu IQX) expected to drive H2 growth, but Q1 2026 results will be challenging.


Baxter International Inc. (BAX) Q4 2025 Earnings Call Transcript

- **Dividend Cut & Deleveraging**: $0.01/share dividend to free $300M/year for debt reduction. 
- **Segment Weakness**: ITT division sales -4% due to pump issues; HST margin down 460bps. 
- **2025 EPS Guidance**: $2.35-$2.40 (down from $2.42-$2.52). 
- **Novum IQ Resolution**: Field actions ongoing; Spectrum IQ sales growth as alternative. 
- **Fluid Conservation**: U.S. IV Solutions demand below pre-Hurricane levels.

**CEO Summary Section**
- **Business Stabilization**: CEO Andrew Heider emphasized three priorities: stabilizing underperforming divisions (e.g., Infusion Therapies), strengthening the balance sheet through dividend reduction, and driving continuous improvement via the new Baxter GPS system.
- **Financial Performance**: Q3 2025 sales from continuing operations were $2.8B (5% YoY reported growth), with adjusted EPS of $0.69 (41% YoY increase). Infusion Therapies & Technologies division sales declined 4% due to Novum IQ Large Volume Pump shipment hold and customer transitions to Spectrum IQ pumps.
- **Balance Sheet Actions**: Dividend cut to $0.01/share starting Q1 2026, freeing $300M annually for deleveraging. 2025 free cash flow expected to remain flat YoY, with Q4 typically the strongest quarter.

**CFO Financial Commentary**
- **Segment Performance**: Medical Products & Therapies (MPT) sales $1.3B (-1% YoY), Healthcare Systems & Technologies (HST) up 2%, Pharmaceuticals up 7% (drug compounding growth offset by injectables softness). 
- **Margins & Costs**: MPT adjusted margin 20.5% (vs. 19.0% YoY), HST margin 13.5% (down 460bps vs. prior year). TSA income ($85M) offset lower sales and tariffs. 
- **2025 Guidance**: Sales growth 4-5% (reported), 1-2% operational growth. 2026 targets: 3x net leverage, $2.35-$2.40 EPS (down from prior $2.42-$2.52 due to lower sales and margin pressure).

**Q&A Highlights**
- **Novum IQ Pump**: Shipment hold expected beyond 2025; Spectrum IQ sales growth as alternative. 
- **Fluid Conservation**: U.S. demand below pre-Hurricane levels; gradual recovery expected. 
- **2026 Outlook**: CEO cautious on top-line growth, citing mix shifts (e.g., compounding vs. injectables).

Baxter International Inc. (BAX) Q3 2025 Earnings Call Transcript

- **Q2 Results**: Sales +4% (1% operational), EPS +28% to $0.59. MPT and Pharma softness offset growth in other segments.
- **Strategic Shifts**: Vantive sale reduces stranded costs; new CEO Andrew Hider to drive innovation.
- **Guidance Update**: 2025 sales 6-7% (3-4% operational), EPS $2.42-2.52. Low end assumes no Novum shipments and sustained fluid conservation.
- **Key Risks**: Fluid conservation, Novum shipment delays, and pharma demand softness.
- **2026 Outlook**: Margin expansion from volume recovery, new products, and stranded cost mitigation.

**【Management Opening Remarks】**
- Clare Trachtman introduced the call, highlighting the sale of Vantive and the focus on operational effectiveness. She emphasized the exclusion of Kidney Care from continuing operations.

**【CEO Summary Section】**
- Q2 sales from continuing operations grew 4% reported and 1% operational, with EPS up 28% to $0.59. Softness in Medical Products & Therapies (MPT) and Pharmaceuticals offset growth in other segments.
- The sale of Vantive reduced stranded costs and created a more agile business. The new CEO, Andrew Hider, will focus on innovation and operational excellence.

**【CFO Financial Commentary】**
- Adjusted gross margin was 14.7%, down 170bps due to Vantive MSA, lower volumes, and mix. SG&A improved 170bps to 22.7% of sales, driven by functional cost reclassification.
- Full-year sales guidance revised to 6-7% reported (3-4% operational), with EPS $2.42-2.52. The low end assumes no Novum shipments and sustained fluid conservation.
- 2026 outlook includes margin expansion from volume recovery, new products, and stranded cost mitigation.

**【Segment Performance】**
- **MPT**: ITT sales down 1% due to fluid conservation. Novum LVP shipments paused temporarily; Spectrum sales offset some decline. CCS division grew 7% internationally.
- **Pharmaceuticals**: Injectables down 4% due to IV push trends. Drug Compounding grew 7% outside the U.S.
- **HST**: CCS sales up 3% in the U.S., driven by care communications. Capital orders declined 40% YoY.

**【Q&A Highlights】**
- **Novum Impact**: Low end of guidance assumes no shipments; high end assumes resumption. Fluid conservation could ease in 2026. TSA income to $170-180M.
- **Stranded Costs**: 40bps impact in 2025, with all costs removed by 2027. TSA roll-off over 24 months post-Vantive sale.
- **Long-Term Growth**: 4-5% revenue growth achievable with Novum recovery, fluid normalization, and new products. 2026 EPS growth driven by volume, margin expansion, and innovation.


Baxter International Inc. (BAX) Q2 2025 Earnings Call Transcript

- **Q1 Beat with 5% Growth**: All segments delivered operational growth, exceeding 3-4% guidance. EPS of $0.55 beat prior range.
- **Tariff Impact Mitigated**: 2025 impact $60-70M, with 70% in H2. Strategies include supplier diversification and pricing adjustments.
- **HST Recovery Sustained**: 6% growth driven by 14% U.S. capital orders, healthy backlog, and digital solution adoption.
- **IV Solutions Normalization**: Allocations removed by May, but 10-12% conservation to persist. Distributor restocking limited to 1.5pts of Q1 growth.
- **Margin Expansion Path**: 2025 operating margin 16-16.5%. Long-term targets via innovation, pricing, and cost optimization.

**【CEO Opening Remarks】**
- Q1 2025 revenue from continuing operations grew 5% YoY to $2.3B, exceeding guidance of 3-4% growth. All three segments (Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals) delivered operational growth.
- Adjusted EPS of $0.55 beat prior guidance of $0.47-$0.50, driven by top-line performance and cost control.
- Emphasized strategic focus on innovation, operational efficiency, and navigating macroeconomic volatility. CEO search for permanent leader is active but no timeline provided.

**【CFO Financial Highlights】**
- Adjusted gross margin: 41.8% (down 160bps YoY due to Vantive MSA costs and supply chain expenses).
- SG&A: $608M (23.2% of sales, 310bps improvement YoY from reclassified costs and expense management).
- R&D: $138M (5.3% of sales, up 50bps YoY for new product investments).
- Tariff impact: $60-70M in 2025, with 70% expected in H2. Mitigation strategies include supplier diversification, inventory build, and targeted pricing.
- Full year 2025 guidance: Sales $9.3-9.5B (7-8% growth), EPS $2.47-$2.55. Q2 EPS $0.59-$0.63.

**【Segment Performance】**
- **Medical Products & Therapies**: 6% growth driven by U.S. infusion systems (Novum IQ pump adoption), nutrition business recovery, and IV solutions supply normalization post-Hurricane Helene.
- **Healthcare Systems & Technologies**: 6% growth led by 14% U.S. capital orders in Care & Connectivity Solutions (Patient Support Systems). International capital orders improving.
- **Pharmaceuticals**: 3% growth from specialty injectables ( gov't orders) offsetting anesthesia decline.

**【Q&A Key Takeaways】**
- **Tariff Mitigation**: 2025 impact $60-70M, 70% in H2. 2026+ strategies include reshoring, alternative suppliers, and exemptions advocacy.
- **IV Solutions**: Conservation expected to persist at 10-12% of U.S. usage, but allocations removed by May 2025. Distributor restocking limited to 1.5pts of Q1 growth.
- **HST Sustainability**: Strong backlog (20% Q2 capital orders), competitive wins in Med-Surg/ICU, and digital workflow solutions driving U.S. growth. Monitoring macroeconomic capital spending trends.
- **Margin Outlook**: 2025 operating margin 16-16.5%. Long-term path to pre-COVID 19%+ margins via innovation, pricing, and cost containment.

Baxter International (BAX (NYSE))-1 May 25-2025 Q1 Earnings call transcript

- **Strategic Momentum**: 2024 revenue growth of 3%, with 5-6% 2025 guidance driven by Nova IQ pump, pharma launches, and cost optimization.
- **Operational Excellence**: 16.5% 2025 margin target, $3B debt reduction, and 3x leverage by end-2025.
- **Innovation Spotlight**: Nova IQ pump delivered 9% Q4 infusion growth; pharma to launch 10+ products in 2025.
- **Risk Management**: Mitigated $110M hurricane impact, offsetting 200+ bps FX headwinds with TSA income and stranded cost savings.

**【CEO & Leadership Overview】**
- **Strategic Transformation Success**: Completed Vantiv sale, divested non-core biopharma assets, and transitioned to a verticalized operating model, driving 3% revenue growth in 2024.
- **Hurricane Recovery Excellence**: Quickly restored North Cove production, mitigating $110M Q4 revenue impact and achieving pre-hurricane levels by Q1 2025.
- **New Leadership Structure**: Appointed Heather Knight as COO to enhance cross-segment collaboration and operational efficiency.

**【CFO Financial Highlights】**
- **2024 Q4 Performance**: $2.75B revenue (1% YoY growth), adjusted EPS $0.58 (11% YoY decline due to hurricane). Full year EPS $1.89 (11% growth).
- **2025 Outlook**: 5-6% revenue growth, 16.5% adjusted operating margin, and $2.45-2.55 EPS, supported by new product launches and cost optimization.
- **Financial Targets**: Leverage ratio to 3x by end-2025, offsetting $345M MSA revenue with TSA income and stranded cost reductions.

**【Key Business Segment Updates】**
- **Medical Products & Therapies (MPT)**: Nova IQ pump launch drove 9% Q4 infusion therapy growth, with full year MPT revenue up 5%.
- **Healthcare Solutions (HST)**: CCS division delivered 9% U.S. capital orders growth, while FLC expects stabilization in 2025 with new product launches.
- **Pharmaceuticals**: 8% Q4 growth, driven by specialty injectables and compounding, with 10+ new product launches planned for 2025.

**【Q&A Key Takeaways】**
- **Growth Cadence**: 2025 growth acceleration in Q4, driven by new product ramps and cost savings.
- **HST Recovery**: Primary care market stabilization and supply constraints resolution expected to support FLC recovery.
- **CEO Search**: Emphasis on innovation, commercial execution, and strategic vision, with interim focus on maintaining momentum.
- **Financial Resilience**: Strong cash flow conversion (80% target) and $3B debt repayment post-Vantiv sale.

Actual															0.82	0.64	0.83	0.8	0.76	0.8	1.02	1.04	0.93	0.87	0.82	0.88	0.59	0.66	0.82	0.88	0.65	0.68	0.49	0.58	0.55	0.59	0.69	0.36
Forecast															0.7315	0.7044	0.728	0.7575	0.6456	0.7489	0.9378	1.0255	0.8012	0.8735	0.8152	0.9395	0.4938	0.5996	0.6671	0.8644	0.6074	0.6624	0.7766	0.5283	0.4835	0.6104	0.5978	0.5402	0.3213
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+12.10%	-9.14%	+14.01%	+5.61%	+17.72%	+6.82%	+8.77%	+1.41%	+16.08%	-0.40%	+0.59%	-6.33%	+19.48%	+10.07%	+22.92%	+1.80%	+7.01%	+2.66%	-36.90%	+9.79%	+13.75%	-3.34%	+15.42%	-33.36%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	2.80B	2.72B	2.97B	3.18B	2.95B	3.10B	3.23B	3.51B	3.71B	3.75B	3.77B	3.89B	3.65B	3.71B	3.71B	3.88B	3.59B	3.81B	2.70B	2.75B	2.63B	2.81B	2.83B	2.97B	--
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	2.73B	2.87B	2.83B	3.12B	2.90B	3.11B	3.23B	3.30B	3.68B	3.88B	3.77B	3.77B	3.60B	3.79B	3.70B	3.81B	3.55B	3.75B	3.85B	2.67B	2.59B	2.82B	2.88B	2.84B	2.62B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+2.45%	-5.18%	+4.93%	+2.07%	+1.67%	-0.37%	-0.01%	+6.50%	+0.79%	-3.41%	+0.19%	+3.18%	+1.32%	-2.07%	+0.29%	+2.07%	+1.08%	+1.52%	-29.83%	+2.97%	+1.45%	-0.45%	-1.48%	+4.87%	0.00%

BAX

BAX fundamentals

BAX Q1 2026 Earnings Preview

Earnings Call

You can ask Aime

BAX

BAX fundamentals

BAX Q1 2026 Earnings Preview

Earnings Call

BAX Earnings Call Summary for Q1/2026Upcoming Apr 12, 2026

BAX Earnings Call Summary for Q4/20258:30 AM on Feb 12, 2026

BAX Earnings Call Summary for Q3/20258:30 AM on Oct 30, 2025

BAX Earnings Call Summary for Q2/20258:30 AM on Jul 31, 2025

BAX Earnings Call Summary for Q1/20258:30 AM on May 1, 2025

You can ask Aime